Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
复制标题
DOI：
10.1007/s00277-016-2818-4
复制
发表时间：
2017-01-01
影响因子：
3.5
通讯作者：
Cha, Hee Jeong
中科院分区：
文献类型：
--
作者：
Jo, Jae-Cheol;Kim, Misung;Cha, Hee Jeong
程序性细胞死亡-1（PD-1）和程序性细胞死亡配体1（PD-L1）是肿瘤免疫治疗的新靶点。本研究旨在探讨PD-1和PD-L1在鼻型结源性自然杀伤/TaEurocell淋巴瘤（ENKTL）中的表达及其临床病理学特征。我们在79例ENKTL活检样本中进行了PD-1和PD-L1免疫染色，并回顾性分析了来自四家三级转诊医院的所有79例患者的医疗记录。评价肿瘤细胞和/或浸润性免疫细胞的PD-1和PD-L1表达。PD-L1在肿瘤细胞和浸润性免疫细胞中的表达率分别为79.7%和78.5%，而PD-1在肿瘤细胞和浸润性免疫细胞中的表达率分别为1.3%和11.4%。肿瘤细胞和浸润性免疫细胞中的PD-L1阳性与低国际预后指数（IPI）显著相关（分别为P = 0.044和0.037）。血清乳酸脱氢酶正常范围的患者显示肿瘤细胞中PD-L1阳性率显著较高（P = 0.020）。与肿瘤细胞和浸润免疫细胞PD-L1阴性的患者相比，PD-L1阳性患者的总生存期有更好的趋势（分别为P = 0.498和0.435）。ENKTL中PD-L1的表达率高达79.7%，而PD-1的表达率很低。这是第一份根据PD-1和PD-L1表达描述ENKTL临床病理特征和生存结局的报告。
Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are new therapeutic targets in cancer immunotherapy. The aim of this study was to investigate the clinicopathological characteristics of PD-1 and PD-L1 expression in extranodal natural killer/TaEurocell lymphoma, nasal type (ENKTL). We performed PD-1 and PD-L1 immunostaining in 79 ENKTL biopsy samples and retrospectively analyzed medical records of all 79 patients from four tertiary referral hospitals. The expression of PD-1 and PD-L1 by tumor cells and/or infiltrating immune cells was evaluated. The expression rates of PD-L1 in tumor cells and infiltrating immune cells were 79.7 and 78.5 %, respectively, whereas PD-1 in tumor cells and infiltrating immune cells were 1.3 and 11.4 %. The PD-L1 positivity in tumor cells and infiltrating immune cells was significantly associated with low international prognostic index (IPI) (P = 0.044 and 0.037, respectively). Patients with normal range of serum lactate dehydrogenase demonstrated a significantly higher PD-L1 positivity in tumor cells (P = 0.020). PD-L1-positive patients had a trend toward better overall survival compared with that in patients with PD-L1-negative in tumor cells and infiltrating immune cells (P = 0.498 and 0.435, respectively). The expression rate of PD-L1 was up to 79.7 % in ENKTL, while PD-1 expression rate was very low. This is the first report describing the clinicopathological features and survival outcome according to expression of PD-1 and PD-L1 in ENKTL.